Adipose Derived Stromal Vascular Fraction and the FDA: The Cell Surgical Network PositionMonday, 21 April 2014 at 14:00 Add to Calendar ▼2014-04-21 14:00:002014-04-21 15:00:00Europe/LondonAdipose Derived Stromal Vascular Fraction and the FDA: The Cell Surgical Network PositionClinical Translation of Stem Cells 2014 in Palm Springs, California, USAPalm Springs, California, USASELECTBIOenquiries@selectbiosciences.com Over the last two years the Cell Surgical Network (CSN) has fielded several criticisms from a number of scientists and bio-ethicists questioning their right to deploy adipose derived SVF. Code of Federal Regulation 21 part 1271 provides a list of elements that allow the FDA to determine whether Human Cells, Tissues and Tissue Products are a drug that can be regulated by the FDA. Letters from FDA Tissue Reference Groups have been circulated as proof that groups such as CSN are in violation of these FDA regulations. This presentation will argue that CSN is indeed in full compliance of the FDA regulations. Further it will address the controversy and point out how these misrepresentations have gained so much traction with many groups of doctors, scientists and ethicists. |